Alnylam's RSV Therapy in Limbo After Phase IIb Miss
By Catherine Shaffer
Thursday, May 31, 2012
The future of Alnylam Pharmaceuticals Inc.'s RNAi candidate for respiratory syncytial virus (RSV), ALN-RSV01, could be either continued development or total termination, according to CEO John Maraganore, following the drug's failure to hit its primary endpoint in a Phase IIb trial against progressive bronchiolitis obliterans syndrome (BOS) in lung transplant patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.